Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3529

1.

One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.

Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team.

N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808.

2.

Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.

Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK.

Clin Drug Investig. 2019 Feb 27. doi: 10.1007/s40261-019-00764-x. [Epub ahead of print] Erratum in: Clin Drug Investig. 2019 Mar 20;:.

PMID:
30810914
3.

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?

Schmaltz CAS, Demitto FO, Sant'Anna FM, Rolla VC.

Mem Inst Oswaldo Cruz. 2019 Feb 11;114:e180420. doi: 10.1590/0074-02760180420.

4.

Treatment of Mycobacterium avium Complex Pulmonary Disease.

Kwon YS, Koh WJ, Daley CL.

Tuberc Respir Dis (Seoul). 2019 Jan;82(1):15-26. doi: 10.4046/trd.2018.0060. Review.

5.

Mucoadhesive guargum hydrogel inter-connected chitosan-g-polycaprolactone micelles for rifampicin delivery.

Yuan X, Amarnath Praphakar R, Munusamy MA, Alarfaj AA, Suresh Kumar S, Rajan M.

Carbohydr Polym. 2019 Feb 15;206:1-10. doi: 10.1016/j.carbpol.2018.10.098. Epub 2018 Oct 29.

PMID:
30553301
6.

Metabolomic Study to Determine the Mechanism Underlying the Effects of Sagittaria sagittifolia Polysaccharide on Isoniazid- and Rifampicin-Induced Hepatotoxicity in Mice.

Ke XH, Wang CG, Luo WZ, Wang J, Li B, Lv JP, Dong RJ, Ge DY, Han Y, Yang YJ, Tu-Erxun RY, Liu HS, Wang YC, Liao Y.

Molecules. 2018 Nov 27;23(12). pii: E3087. doi: 10.3390/molecules23123087.

7.

Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.

Schein YL, Madebo T, Andersen HE, Arnesen TM, Dyrhol-Riise AM, Tveiten H, White RA, Winje BA.

BMC Infect Dis. 2018 Nov 19;18(1):587. doi: 10.1186/s12879-018-3468-z.

8.

Predictors of therapeutic failure among patients with acute brucellosis treated by dual therapy with doxycycline-rifampin.

Alsayed Hasanain AF, El-Masry MA, Zayed AAH, Nafee AMA, Attia RAH, Abdel-Aal SM.

Trop Med Int Health. 2019 Feb;24(2):185-191. doi: 10.1111/tmi.13179. Epub 2018 Nov 29.

PMID:
30411836
9.

Management of De Novo Mycobacterial Infection After Lung Transplantation Without Rifampicin: Case Series of a Single Institution.

Suzuki H, Matsuda Y, Noda M, Oishi H, Watanabe T, Sado T, Yamada M, Tamada T, Okada Y.

Transplant Proc. 2018 Nov;50(9):2764-2767. doi: 10.1016/j.transproceed.2018.03.058. Epub 2018 Mar 15.

PMID:
30401393
10.

Therapeutic outcome of spinal implant infections caused by Staphylococcus aureus: A retrospective observational study.

Cho OH, Bae IG, Moon SM, Park SY, Kwak YG, Kim BN, Yu SN, Jeon MH, Kim T, Choo EJ, Lee EJ, Kim TH, Choi SH, Chung JW, Kang KC, Lee JH, Lee YM, Lee MS, Park KH.

Medicine (Baltimore). 2018 Oct;97(40):e12629. doi: 10.1097/MD.0000000000012629.

11.

Antibiotics for treating scrub typhus.

El Sayed I, Liu Q, Wee I, Hine P.

Cochrane Database Syst Rev. 2018 Sep 24;9:CD002150. doi: 10.1002/14651858.CD002150.pub2. Review.

PMID:
30246875
12.

Clostridium difficile arising in a patient with hidradenitis suppurativa on clindamycin and rifampin.

Bessaleli E, Scheinfeld N.

Dermatol Online J. 2018 May 15;24(5). pii: 13030/qt3x20x5rj.

13.

Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).

Yotsu RR, Richardson M, Ishii N.

Cochrane Database Syst Rev. 2018 Aug 23;8:CD012118. doi: 10.1002/14651858.CD012118.pub2. Review.

PMID:
30136733
14.

Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).

Lupien A, Vocat A, Foo CS, Blattes E, Gillon JY, Makarov V, Cole ST.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e00840-18. doi: 10.1128/AAC.00840-18. Print 2018 Nov.

PMID:
30126954
15.

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.

Gardin A, Gray C, Neelakantham S, Huth F, Davidson AM, Dumitras S, Legangneux E, Shakeri-Nejad K.

Eur J Clin Pharmacol. 2018 Dec;74(12):1593-1604. doi: 10.1007/s00228-018-2533-2. Epub 2018 Aug 13.

PMID:
30105453
16.

Updates in the Treatment of Active and Latent Tuberculosis.

Haas MK, Belknap RW.

Semin Respir Crit Care Med. 2018 Jun;39(3):297-309. doi: 10.1055/s-0038-1660863. Epub 2018 Aug 2. Review.

PMID:
30071545
17.

Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.

Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti A.

N Engl J Med. 2018 Aug 2;379(5):440-453. doi: 10.1056/NEJMoa1714283.

18.

Safety and Side Effects of Rifampin versus Isoniazid in Children.

Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li PZ, Hill PC, Schwartzman K, Benedetti A, Menzies D.

N Engl J Med. 2018 Aug 2;379(5):454-463. doi: 10.1056/NEJMoa1714284.

19.

Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

Lo DK, Muhlebach MS, Smyth AR.

Cochrane Database Syst Rev. 2018 Jul 21;7:CD009650. doi: 10.1002/14651858.CD009650.pub4. Review.

PMID:
30030966
20.

Rifampin.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Supplemental Content

Loading ...
Support Center